Gilead Reports real-world evidence Data for Secukinumab in COVID-19

Gilead today announced real-world evidence results for secukinumab in patients with COVID-19. The study demonstrated that secukinumab achieves complete response compared to standard of care or placebo. These results provide important insights into the treatment of COVID-19 and support the continued development of secukinumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.